The potential of sodium-glucose cotransporter 2 inhibitors for the treatment of systemic right ventricular failure in adults with congenital heart disease

AIMS: Given the compelling evidence on the effectiveness of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in the conventional heart failure population, SGLT2i deserve exploration in systemic right ventricular (sRV) failure. The initial experience with dapagliflozin in sRV failure patients is de...

Descripción completa

Detalles Bibliográficos
Autores principales: Neijenhuis, Ralph M. L., Nederend, Marieke, Jongbloed, Monique R. M., Kiès, Philippine, Rotmans, Joris I., Vliegen, Hubert W., Jukema, J. Wouter, Egorova, Anastasia D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Cardiovascular Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10330719/
https://www.ncbi.nlm.nih.gov/pubmed/37435053
http://dx.doi.org/10.3389/fcvm.2023.1093201

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10330719/
https://www.ncbi.nlm.nih.gov/pubmed/37435053
http://dx.doi.org/10.3389/fcvm.2023.1093201

Ejemplares similares